COGT

Cogent Biosciences, Inc. COGT

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-96.41M

Quarter to Jun 30

Free cash flow

$-77.64M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$7.76B total
FMR LLC
$995.76M+10.6%
BlackRock, Inc.
$671.55M+8.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$312.40M+10.1%
VANGUARD CAPITAL MANAGEMENT LLC
$286.86M+7.5%
STATE STREET CORP
$269.54M+23.0%
Jupiter Topco LLC
$261.28M--
Fairmount Funds Management LLC
$212.98M0.0%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$193.74M-44.6%
TCG Crossover Management, LLC
$187.87M-1.9%
PRICE T ROWE ASSOCIATES INC /MD/
$180.06M+44.8%
GEODE CAPITAL MANAGEMENT, LLC
$174.53M+21.9%
WELLINGTON MANAGEMENT GROUP LLP
$168.11M+21.4%
LORD, ABBETT & CO. LLC
$142.88M+0.9%
Kynam Capital Management, LP
$141.92M-9.2%
Polar Capital Holdings Plc
$125.11M-12.6%
Commodore Capital LP
$118.03M+5.6%
LINDEN ADVISORS LP
$108.94M+2.8%
Invesco Ltd.
$100.97M+7.4%
Woodline Partners LP
$100.74M+72.4%
Pictet Asset Management Holding SA
$92.63M+33.1%
Octagon Capital Advisors LP
$90.94M0.0%
RTW INVESTMENTS, LP
$89.36M-57.7%
GOLDMAN SACHS GROUP INC
$88.57M-48.4%
Candriam S.C.A.
$80.74M+37.7%
Deep Track Capital, LP
$77.40M+100.0%
See all 339 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/COGT

Earnings Per Share

13fpro.ai/company/COGT

Loading ratio trend…

COGT key financials by period

Reported revenue, net income and operating margin by fiscal year, from Cogent Biosciences, Inc.'s annual filings on SEC EDGAR.

Cogent Biosciences, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2020$7.9M$-74.8M—
FY 2019$22.5M$-31.8M-143.0%
FY 2018$9.7M$-34.5M—
FY 2017$8.4M$-25.5M—
Source: COGT filings on SEC EDGAR →

COGT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in COGT

1 transaction in COGT reported by 1 member of Congress under the STOCK Act, most recent trade Dec 12, 2022. Reported transactions, not recommendations.

All Congress stock trades →

About Cogent Biosciences, Inc. (COGT): stock profile, AI score and financials

Cogent Biosciences, Inc. (COGT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. COGT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Cogent Biosciences, Inc. reports net income of $-96.4M, free cash flow of $-77.6M. Top institutional holders of COGT by reported 13-F value include FMR, BlackRock, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. COGT trades on the Nasdaq exchange and files with the SEC under CIK 1622229. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COGT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cogent Biosciences, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1622229 →